Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening
Launched by MASSACHUSETTS GENERAL HOSPITAL · Mar 1, 2019
Trial Information
Current as of August 26, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a new device called the LymphaTech Scanner, which is used to measure the size of the arms in women who have had breast cancer surgery. The goal is to see how well this device works compared to another established method called the Perometer for screening breast cancer-related lymphedema, a condition that can cause swelling in the arms after surgery.
To participate in this study, women aged 18 and older who have been diagnosed with breast cancer and are planning to have surgery on one breast may be eligible. However, those with certain conditions, such as previous lymphedema, current infections, or specific health issues, will not be able to join. Participants will undergo scans to measure their arm sizes, and the study aims to gather important information about the ease of use and accuracy of the LymphaTech Scanner. If you join, you can help researchers understand better ways to monitor and manage lymphedema in breast cancer survivors.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Participants must have histologically or cytologically confirmed invasive or in-situ carcinoma of the breast and will undergo unilateral breast cancer surgery
- • Age \>18 years.
- • Ability to understand and the willingness to verbally consent to the trial
- Exclusion Criteria:
- • History of primary lymphedema.
- • Any patient with a current case of cellulitis.
- • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- • Participants unable to abduct upper-extremity perpendicular to body or to stand comfortably without aid for several minutes, both of which are necessary to perform a LymphaTech Scan
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Alphonse G. Taghian, MD
Principal Investigator
Dana-Farber Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials